Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2022 on file Net Income-$14.76M-$14.76MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$15,959,000N/M Operating Cash Flowderived-$11,062,000N/M Free Cash Flowderived-$11,079,000N/M ended Dec 31, 2023 · filed Mar 14, 2024 · 74 d after period end